Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Beuzeboc

Showing results (81-90 of 128) with videos related to

Pageof 13
Sort By:
Anti-Cancer Drugs|September 10, 2010
A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancerAhmed Dahmani, Ludmilla de Plater, Charlotte Guyader, et al.
Journal of Biomedicine & Biotechnology|September 17, 2003
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2Susy Scholl, Patrick Squiban, Nadine Bizouarne, et al.
European Urology|October 8, 2013
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective studyKarim Fizazi, Rémi Delva, Armelle Caty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancerStéphane Oudard, Eugeniu Banu, Philippe Beuzeboc, et al.
European Urology|May 20, 2014
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted TherapiesNader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al.
Pharmaceutics|February 25, 2023
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate CancerJean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, et al.
Anticancer Research|March 19, 2017
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational StudyVeronique Dieras, Simona Pop, Frederique Berger, et al.
Cancer Treatment Reviews|September 26, 2016
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literatureGwenaëlle Gravis, François Audenet, Jacques Irani, et al.
International Journal of Molecular Sciences|June 19, 2024
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate CancerEmmanuel Chamorey, Marc Pujalte-Martin, Jean-Marc Ferrero, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 23, 2005
[Prostatic cancer]Michel Soulié, Christian Barré, Philippe Beuzeboc, et al.
Pageof 13

Showing results (81-90 of 128) with videos related to

Sort By:
Pageof 13
Anti-Cancer Drugs|September 10, 2010
A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancerAhmed Dahmani, Ludmilla de Plater, Charlotte Guyader, et al.
Journal of Biomedicine & Biotechnology|September 17, 2003
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2Susy Scholl, Patrick Squiban, Nadine Bizouarne, et al.
European Urology|October 8, 2013
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective studyKarim Fizazi, Rémi Delva, Armelle Caty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancerStéphane Oudard, Eugeniu Banu, Philippe Beuzeboc, et al.
European Urology|May 20, 2014
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted TherapiesNader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al.
Pharmaceutics|February 25, 2023
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate CancerJean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, et al.
Anticancer Research|March 19, 2017
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational StudyVeronique Dieras, Simona Pop, Frederique Berger, et al.
Cancer Treatment Reviews|September 26, 2016
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literatureGwenaëlle Gravis, François Audenet, Jacques Irani, et al.
International Journal of Molecular Sciences|June 19, 2024
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate CancerEmmanuel Chamorey, Marc Pujalte-Martin, Jean-Marc Ferrero, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 23, 2005
[Prostatic cancer]Michel Soulié, Christian Barré, Philippe Beuzeboc, et al.
Pageof 13